InflaRx on large white.jpg
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
November 09, 2022 07:40 ET | InflaRx N.V.
Randomized, double-blind, placebo-controlled Phase I trial of orally administered complement inhibitor INF904 initiatedStudy designed as single ascending dose to determine safety, tolerability and...
scilogo.jpg
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
November 07, 2022 08:45 ET | SciSparc Ltd
Meets primary endpoints- SCI-110 administration was found to be safe at all tested dosesSCI-110 treatment was also found to reduce agitation - 75% of patients did not need to use additional medication...
logo1.png
CROSSJECT - Validation clinique de l’efficacité de ZENEO® pour l’injection intramusculaire de midazolam
November 02, 2022 03:00 ET | CROSSJECT
Communiqué de presse Validation clinique de l’efficacité de ZENEO® pour l’injection intramusculaire de midazolam • Paramètres primaires atteints et résultats conformes aux attentes Pas d’impact du...
logo1.png
CROSSJECT - CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM
November 02, 2022 03:00 ET | CROSSJECT
Press release CLINICAL DEMONSTRATION OF ZENEO® EFFICIENCY FOR INTRAMUSCULAR INJECTION OF MIDAZOLAM • Primary endpoints met and results in line with expectations• No impact of clothing on the...
LOGO.png
IMAC Holdings, Inc. Announces Completion of Third Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
September 09, 2022 09:22 ET | IMAC Holdings, Inc.
BRENTWOOD, Tenn., Sept. 09, 2022 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) (“IMAC” or “the Company”), today announces it has completed the third cohort of its Phase 1 clinical trial for...
Florida Cancer Specialists & Research Institute Physicians Present Cancer Care Advancements at Global Oncology Gathering
September 08, 2022 12:30 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is among the latest cutting-edge developments and findings...
Ecofibre and Ananda Professional Open Registration for CBD360
July 19, 2022 16:00 ET | Ecofibre Ltd.
GEORGETOWN, Ky., July 19, 2022 (GLOBE NEWSWIRE) -- Ananda Professional has provided training and education to over 5,000 healthcare professionals and pharmacists through various events and seminars...
purple-logo2020.png
Purple Biotech Announces Executive Leadership Changes
July 14, 2022 07:30 ET | Purple Biotech Ltd.
Gil Efron appointed as Chief Executive Officer Isaac Israel to transition to advisor role, continue as Board member REHOVOT, Israel, July 14, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd....
scilogo.jpg
SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc.
June 07, 2022 08:30 ET | SciSparc Ltd
TEL AVIV, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the...
scilogo.jpg
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
June 02, 2022 08:30 ET | SciSparc Ltd
No dedicated treatment currently available for cocaine addiction TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical...